Molecular Pathways Controlling Ovarian Gene Expression
控制卵巢基因表达的分子途径
基本信息
- 批准号:7913605
- 负责人:
- 金额:$ 22.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-02-01 至 2014-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcuteAddressAntibodiesAntralApoptosisAromataseAtretic FolliclesBiologicalBiological AssayCell Culture TechniquesCell DeathCell ProliferationCell physiologyCellsCodeCollaborationsDefectDevelopmentDifferentiation and GrowthDominant-Negative MutationElectrophoretic Mobility Shift AssayEmbryoEnzymesEstradiolEtiologyFemaleFertilityFollicle Stimulating HormoneFollicle Stimulating Hormone ReceptorGATA4 transcription factorGene ExpressionGene TargetingGenesGlycogen Synthase Kinase 3Gonadal Steroid HormonesGrowthGrowth FactorHormonesImmunohistochemistryImmunoprecipitationIn VitroInfertilityInvestigationKnockout MiceKnowledgeLightLysineMAPK14 geneMediatingModificationMolecularMusOvarianOvarian CyclesOvarian DiseasesOvarian Granulosa CellOvaryPaperPathway interactionsPeptidesPhosphorylationPhosphotransferasesPhysiologicalPituitary HormonesPlayProductionProliferatingProtein CProteinsPublishingRegulationRegulator GenesRoleSmall Interfering RNAStagingSteroid biosynthesisSteroidsSystemTechniquesTechnologyTranscription CoactivatorTransgenic ModelWestern BlottingWomanbasecofactordesignfolliculogenesisgene repressiongranulosa cellgranulosa cell tumorimproved functioningin uteroin vivoinhibinintraovarianmutantoocyte maturationoverexpressionpublic health relevanceresponsetranscription factor
项目摘要
DESCRIPTION (provided by applicant): Coordinated activation and repression of genes are essential for the normal progress of the ovarian cycle. Ovarian granulosa cells express high levels of the transcription factors GATA-4 and GATA-6. In cell cultures, these transcription factors were shown to play key roles in the expression of enzymes involved in steroidogenesis. We have demonstrated in several recently published papers that GATA-4 is critical for the production of estradiol, which is essential for granulosa cell proliferation and follicle maturation. In addition, the finding that low expression of GATA-4 is associated with follicular cell death suggests that this factor also plays a survival role in the ovary. Because GATA-4 and GATA-6 null mice are embryonic lethal, the ultimate role of GATA in ovarian function remains unknown. This study is therefore designed to determine the physiological role of GATA-4 and GATA-6 in ovarian steroidogenesis, follicular development, and female fertility. The specific aims of this study are: 1- To generate ovarian-specific GATA-4 and GATA-6 null mice in order to find out the explicit roles of these transcription factors in the ovary in vivo. The Cre-lox technology will be used to delete part of the coding region of GATA-4, GATA-6, or their combination. We expect these mice to have severe defects in steroid production and in follicular development. 2- To determine the effect of GATA-4 and GATA-6 deletion on ovarian cells in vitro. Granulosa cells lacking GATA-4, GATA-6, or both will be used to examine the specific roles of these factors in steroidogenesis, cell proliferation, granulosa-cell hormone response, and gene expression. 3- To identify those genes that are regulated by GATA-4 and GATA-6 in fully functional ovaries in vivo, we will use ChIP-on-chip assays. All the results obtained to date indicate that GATA-4 and GATA-6 may play a crucial role in the normal function of the ovary. We expect from this investigation to clearly define the function of GATA-4 and GATA-6 in the steroidogenic capacity and growth of granulosa cells, to determine whether GATA-4 and GATA-6 have redundant effects on these cells, and to identify GATA-4 and GATA-6 target genes in the ovary. This study will not only provide critically important information on the regulatory mechanism underlying normal ovarian function but also may shed light on ovarian diseases due to improper granulosa cell function such as granulosa cell tumors and infertility. PUBLIC HEALTH RELEVANCE: The roles of the transcription factors GATA-4 and GATA-6 in folliculogenesis and fertility will be addressed. These studies will contribute to better understanding of the cellular and molecular mechanisms that control ovarian function and improve our knowledge of the etiology of ovarian diseases such as granulosa cell tumors and infertility.
描述(由申请人提供):基因的协调激活和抑制对于卵巢周期的正常进展至关重要。卵巢颗粒细胞表达高水平的转录因子GATA-4和GATA-6。在细胞培养物中,这些转录因子被证明在涉及类固醇生成的酶的表达中起关键作用。我们在最近发表的几篇论文中证明了GATA-4对于雌二醇的产生至关重要,这对于颗粒细胞增殖和卵泡成熟至关重要。此外,GATA-4低表达与卵泡细胞死亡有关的发现表明,该因素在卵巢中也起生存作用。由于GATA-4和GATA-6无效小鼠是胚胎致死的,因此GATA在卵巢功能中的最终作用仍然未知。因此,这项研究旨在确定GATA-4和GATA-6在卵巢类固醇生成,卵泡发育和女性生育能力中的生理作用。这项研究的具体目的是:1-生成卵巢特异性GATA-4和GATA-6无效小鼠,以找出这些转录因子在体内卵巢中的明确作用。 CRE-LOX技术将用于删除GATA-4,GATA-6的编码区域的一部分或它们的组合。我们预计这些小鼠在类固醇产生和卵泡发育方面会有严重的缺陷。 2-确定GATA-4和GATA-6缺失对体外卵巢细胞的影响。缺乏GATA-4,GATA-6的颗粒细胞将用于检查这些因子在类固醇生成,细胞增殖,颗粒细胞激素反应和基因表达中的特定作用。 3-鉴定在体内功能性卵巢中受GATA-4和GATA-6调节的基因,我们将使用芯片片上的芯片分析。迄今为止获得的所有结果表明,GATA-4和GATA-6在卵巢的正常功能中可能起着至关重要的作用。我们期望这项研究清楚地确定GATA-4和GATA-6在颗粒细胞的类固醇生成能力和生长中的功能,以确定GATA-4和GATA-6是否对这些细胞具有冗余作用,并鉴定GATA-4和GATA-4和GATA-6靶基因。这项研究不仅将提供有关正常卵巢功能的调节机制的至关重要的信息,而且由于颗粒细胞功能不当,例如颗粒细胞肿瘤和不孕症,可能会阐明卵巢疾病。公共卫生相关性:将解决转录因子GATA-4和GATA-6在卵泡发生和生育方面的作用。这些研究将有助于更好地理解控制卵巢功能的细胞和分子机制,并提高我们对卵巢疾病(例如颗粒细胞肿瘤和不育)病因的了解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARLOS OSCAR STOCCO其他文献
CARLOS OSCAR STOCCO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARLOS OSCAR STOCCO', 18)}}的其他基金
Salt-Inducible Kinase Regulation of Ovarian Granulosa Cells
卵巢颗粒细胞的盐诱导激酶调节
- 批准号:
10011939 - 财政年份:2019
- 资助金额:
$ 22.53万 - 项目类别:
Salt-Inducible Kinase Regulation of Ovarian Granulosa Cells
卵巢颗粒细胞的盐诱导激酶调节
- 批准号:
10165768 - 财政年份:2019
- 资助金额:
$ 22.53万 - 项目类别:
Salt-Inducible Kinase Regulation of Ovarian Granulosa Cells
卵巢颗粒细胞的盐诱导激酶调节
- 批准号:
10406988 - 财政年份:2019
- 资助金额:
$ 22.53万 - 项目类别:
Salt-Inducible Kinase Regulation of Ovarian Granulosa Cells
卵巢颗粒细胞的盐诱导激酶调节
- 批准号:
10643707 - 财政年份:2019
- 资助金额:
$ 22.53万 - 项目类别:
Regulation of Aromatase Expression in the Corpus Luteum
黄体中芳香酶表达的调节
- 批准号:
8045278 - 财政年份:2011
- 资助金额:
$ 22.53万 - 项目类别:
Regulation of Aromatase Expression in the Corpus Luteum
黄体中芳香酶表达的调节
- 批准号:
8206281 - 财政年份:2011
- 资助金额:
$ 22.53万 - 项目类别:
Molecular Pathways Controlling Ovarian Gene Expression
控制卵巢基因表达的分子途径
- 批准号:
8044047 - 财政年份:2009
- 资助金额:
$ 22.53万 - 项目类别:
Molecular Pathways Controlling Ovarian Gene Expression
控制卵巢基因表达的分子途径
- 批准号:
8431437 - 财政年份:2009
- 资助金额:
$ 22.53万 - 项目类别:
Molecular Pathways Controlling Ovarian Gene Expression
控制卵巢基因表达的分子途径
- 批准号:
7761207 - 财政年份:2009
- 资助金额:
$ 22.53万 - 项目类别:
Molecular Pathways Controlling Ovarian Gene Expression
控制卵巢基因表达的分子途径
- 批准号:
8212331 - 财政年份:2009
- 资助金额:
$ 22.53万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Role of skeletal muscle IPMK in nutrient metabolism and exercise
骨骼肌IPMK在营养代谢和运动中的作用
- 批准号:
10639073 - 财政年份:2023
- 资助金额:
$ 22.53万 - 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:
10727268 - 财政年份:2023
- 资助金额:
$ 22.53万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 22.53万 - 项目类别:
HDAC3 as a therapeutic target for intracerebral hemorrhage
HDAC3作为脑出血的治疗靶点
- 批准号:
10701321 - 财政年份:2023
- 资助金额:
$ 22.53万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10917559 - 财政年份:2023
- 资助金额:
$ 22.53万 - 项目类别: